FierceBiotech23d
Gilead loses interest in Arcus' kidney cancer rival to Merck's Welireg
Gilead Sciences has defied analysts’ expectations by passing on its chance to license Arcus Biosciences’ potential rival to Merck & Co.’s kidney cancer drug Welireg. Gilead had the right to ...
STAT1mon
Gilead’s short-term win threatens the future of pharmaceutical public-private partnerships
Gilead’s short-term win could come at massive cost to the future of pharmaceutical innovation and to the health of the American public. The U.S. government filed the lawsuit in 2019, alleging ...
FiercePharma9d
Gilead sets aside $200M for potential settlement over HIV drug speaker program
Weeks after settling a five-year patent dispute with the U.S. government for an undisclosed sum, California's Gilead Sciences revealed that it has set aside $200 million for a potential resolution ...
Seeking Alpha1mon
Gilead stock climbs 6% following Q4 report, dividend hike
Shares of Gilead (NASDAQ:GILD) rose 6% post-market after the company released a Q4 earnings report that beat the Street and hiked its quarterly dividend. For Q4, Gilead (NASDAQ:GILD) posted non ...